March 2 (Reuters) – Eli Lilly CFO Lucas Montarce said on Monday it is preparing to launch its new oral obesity drug, orforglipron, in the United States as early as the second quarter of this year, once it gets approval from the Food and Drug Administration.
“On track in the US, expect to see potentially that product coming into the market as early as Q2,” Montarce said at the TD Cowen healthcare conference.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Shinjini Ganguli)
